2-[4-(3-Pyridin-3-yl-1,2,4-triazol-1-yl)butyl]isoindole-1,3-dione | 173838-65-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-[4-(3-Pyridin-3-yl-1,2,4-triazol-1-yl)butyl]isoindole-1,3-dione
• CAS: 173838-65-8
• 化学式: C₁₉H₁₇N₅O₂
• 分子量: 347.376
• InChiKey: LPLSBTOELZWKPY-UHFFFAOYSA-N

物化性质

• 沸点：
  588.7±60.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  81
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-[4-(3-Pyridin-3-yl-1,2,4-triazol-1-yl)butyl]isoindole-1,3-dione 在 一水合肼 作用下， 以 乙醇 为溶剂， 生成 4-(5-(pyridin-3-yl)-2H-tetrazol-2-yl)butylamine
  参考文献：
  名称：

  Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens

  摘要：

  In the search for new ketolides with improved activities against erythromycin-resistant S. pneumoniae and H. influenzae we synthesized a new 11,12 carbamate ketolide substituted by an imidazo-pyridyl side chain: HMR 3647. This compound demonstrated a potent activity against erythromycin susceptible and resistant pathogens, including penicillin G/erythromycin A-resistant S. pneumoniae and H. influenzae. In vivo, HMR 3647 displayed good pharmacokinetic parameters (Cmax = 2.9 mu g/ml, bioavailability = 49%, AUC(0-8) = 17.2 mu g.h/l, t(1/2) = 1h) and was shown to have a high therapeutic efficacy in mice infected by various respiratory pathogens, including multi-resistant S. pneumoniae and Gram negative bacteria such as H. influenzae. HMR 3647 appears to be a very promising agent for the treatment of respiratory infections and is currently in clinical trials. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00534-x
• 作为产物：
  描述：

  3-(3-吡啶基)-1H-1,2,4-三唑 、 N-(4-溴丁基)邻苯二甲酰亚胺 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-[4-(3-Pyridin-3-yl-1,2,4-triazol-1-yl)butyl]isoindole-1,3-dione
  参考文献：
  名称：

  Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens

  摘要：

  In the search for new ketolides with improved activities against erythromycin-resistant S. pneumoniae and H. influenzae we synthesized a new 11,12 carbamate ketolide substituted by an imidazo-pyridyl side chain: HMR 3647. This compound demonstrated a potent activity against erythromycin susceptible and resistant pathogens, including penicillin G/erythromycin A-resistant S. pneumoniae and H. influenzae. In vivo, HMR 3647 displayed good pharmacokinetic parameters (Cmax = 2.9 mu g/ml, bioavailability = 49%, AUC(0-8) = 17.2 mu g.h/l, t(1/2) = 1h) and was shown to have a high therapeutic efficacy in mice infected by various respiratory pathogens, including multi-resistant S. pneumoniae and Gram negative bacteria such as H. influenzae. HMR 3647 appears to be a very promising agent for the treatment of respiratory infections and is currently in clinical trials. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00534-x